<DOC>
	<DOC>NCT00796107</DOC>
	<brief_summary>This study will determine the safety and efficacy of R1507 in combination with letrozole in patients with advanced breast cancer. In the first part of the study a cohort of patients with advanced breast cancer will receive letrozole 2.5mg po daily in combination with R1507 16mg/kg every 3 weeks. A second cohort of patients who have either progressed or plateaued on letrozole treatment will receive 3-weekly cycles of combination treatment with letrozole and R1507. The anticipated time on study treatment is until disease progression or unacceptable toxicity, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>postmenopausal female patients; stage IV or locally advanced breast cancer; measurable disease; letrozole failure (Part 2); Eastern Cooperative Oncology Group (ECOG) performance status &lt;=2. previous chemotherapy for metastatic breast cancer; concurrent antibody or immunotherapy for advanced disease, within 4 weeks prior to receipt of study drug; history of primary malignancy in 5 years prior to study, excluding adequately treated basal or squamous cell cancer of skin, or cancer in situ of cervix; concurrent radiotherapy, or radiotherapy within 28 days prior to receipt of study drug.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>